Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer

BMC Cancer

Table 2 VEGF-A/VEGFR1, VEGF-A/VEGFR2, VEGF-B/VEGFR1, and VEGF-C/VEGFR2 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer.

		VEGF-A/VEGFR1		VEGF-A/VEGFR2		VEGF-B/VEGFR1		VEGF-C/VEGFR2
			P-value		P-value		P-value		P-value
TNM stage	I+II	13.7 ± 32.6; 1.0	0.198	1.63 ± 8.6; 1.0	0.005	11.2 ± 27.2; 1.0	0.867	2.6 ± 9.3; 0.8	0.003
	III	13.0 ± 31.7; 1.0		0.66 ± 0.4; 0.95		8.1 ± 23.2; 1.0		0.58 ± 0.38; 0.68
	IV	5.2 ± 19.7; 1.0		3.85 ± 16.3; 1.0		5.9 ± 20.0; 1.0		1.95 ± 8.8; 0.84
Tumour grade	G1-2	10.7 ± 29.2; 1.0	0.704	2.05 ± 10.6; 1.0	0.179	8.0 ± 22.9; 0.98	0.956	1.51 ± 8.2; 0.79	0.06
	G3	13.5 ± 32.2; 1.0		0.73 ± 0.4; 0.95		12.9 ± 29.7; 1.0		0.58 ± 0.4; 0.65
Vascular invasion	Absent	13.2 ± 32.2; 1.0	0.276	2.2 ± 11.3; 1.0	0.38	10.7 ± 26.9; 1.0	0.078	1.6 ± 8.9; 0.75	0.412
	Present	6.48 ± 22.0; 1.0		0.78 ± 0.36; 0.98		4.28 ± 15.2; 0.95		0.65 ± 0.38; 0.75
Tumour border configuration	PM	12.4 ± 31.2; 1.0	0.211	1.35 ± 6.3; 1.0	0.006	9.8 ± 25.2; 1.0	0.244	1.2 ± 5.7; 0.79	0.326
	IM	9.83 ± 27.6; 1.0		2.28 ± 12.2; 0.95		7.76 ± 23.2; 0.95		1.48 ± 9.04; 0.75
PTL infiltration	Absent	9.73 ± 27.6; 1.0	0.032	1.56 ± 8.4; 1.0	0.074	8.09 ± 23.5; 1.0	0.356	1.01 ± 4.5; 0.78	0.235
	Present	17.5 ± 36.6; 1.0		2.83 ± 13.6; 1.0		12.3 ± 27.5; 0.87		2.79 ± 14.7; 0.75

Mean ± SD, median values. Kruskal Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.

ISSN: 1471-2407